Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234752 · ClinicalTrials.gov registry record · Phase 2
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
A Phase 2 study, sponsored by Sheppard Pratt Health System.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02234752: Clinical Trial Phase 2 study, sponsored by Sheppard Pratt Health System.
NCT02234752 is a Phase 2 study that was terminated before completion, run by Sheppard Pratt Health System. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02234752, a Phase 2 study, was terminated before completion, sponsored by Sheppard Pratt Health System.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Aim: To examine the efficacy of the combination of galantamine and memantine for the treatment of cognitive deficits in outpatients with schizophrenia. Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in patients with schizophrenia. This is an open-label study to evaluate whether a six week course of galantamine ER and memantine XR is effective in improving the cognitive performance of patients with schizophrenia or schizoaffective disorder. The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). The results of the MATRICS collaborative project recommended the need for standardized cognitive tests that better distinguish the different facets of cognitive dysfunction in schizophrenia. The MCCB will assess the following seven domains: attention/vigilance, reasoning and problem solving, processing speed, social cognition, verbal learning and memory, visual learning and memory, and working memory. The MCCB will be administered at baseline and at the end of the study. We will report total score and each domain score in the MCCB at baseline and six weeks.
Primary Outcome
The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). In schizophrenia, usual composite scores are 20-39. In healthy controls, usual composite scores are normalized to 40-60. Higher values of composite scores mean better cognition. Test scores are normalized to healthy controls, therefore no min-max range is available. Final scores calculated by MATRICS Consensus Cognitive Battery software. Exact minimum/maximum are no
Interventions
- DRUG Memantine XR
- DRUG Galantamine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Why NCT02234752 stopped before completion
NCT02234752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Memantine XR is the first listed.
NCT02234752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02234752 about?
NCT02234752 is a clinical study titled "Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia". Aim: To examine the efficacy of the combination of galantamine and memantine for the treatment of cognitive deficits in outpatients with schizophrenia. Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in patients with schizophrenia. This is an open-label st...
What is the current status of trial NCT02234752?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02234752?
The interventions under investigation include: Memantine XR (DRUG), Galantamine ER (DRUG).
Who is sponsoring clinical trial NCT02234752?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02234752's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia